Dexamethasone intravitreal implant for treating diabetic macular oedema, retinal vein occlusion and non-infectious uveitis

Published on 01 Sep 2023
Last Updated on 01 Sep 2023

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has not recommended listing dexamethasone 0.7 mg intravitreal implant on the MOH List of Subsidised Drugs for treating diabetic macular oedema, macular oedema following retinal vein occlusion and non-infectious uveitis affecting the posterior segment of the eye. The decision was based on the unfavourable clinical and cost-effectiveness of intravitreal dexamethasone implant compared with current treatment options.

Dexamethasone intravitreal implant for treating diabetic macular oedema, retinal vein occlusion and non-infectious uveitis (Published 1 Sep 23) [PDF, 123 KB]

PES Dexamethasone intravitreal implant for treating diabetic macular oedema, retinal vein occlusion and non-infectious uveitis (Published 1 Sep 23) [PDF, 125 KB]